

## Evonik launches EUDRACAP® colon functional capsules in GMP quality at CPHI Frankfurt

October 21, 2025

- EUDRACAP® colon now available for clinical and commercial use
- First functional, ready-to-fill capsule targeting the ileo-colonic region
- Showcasing innovations for oral and parenteral drug delivery at CPHI Frankfurt

**Main press contact**

**Elizabeth Hawkins**

Market Communications  
Health Care  
Phone +49 1749956389  
elizabeth.hawkins@evonik.com

**Alternative press contact**

**Dr. Jürgen Krauter**

Head of Market Communications Evonik  
Phone +49 6181 59-6847  
juergen.krauter@evonik.com

**Essen, Germany.** Evonik's EUDRACAP® colon functional capsules are now available produced under good manufacturing practice (GMP). Launched last year, EUDRACAP® colon is the first functional, ready-to-fill capsule specifically designed to target the ileo-colonic region. The capsule meets the growing demand for precise delivery of sensitive active ingredients – such as live biotherapeutic products (LBPs) – used to treat or prevent a wide range of diseases such as obesity, infections and cancer.

“Enabling the oral delivery of sensitive molecules opens new opportunities for the pharmaceutical industry. I am delighted that our customers can now work on clinical and commercial phases for innovative, breakthrough drugs,” said Thilo Krapfl, Head of Oral Drug Delivery Solutions at Evonik Health Care.

EUDRACAP® colon was developed to meet a critical need in the pharmaceutical market: delivering sensitive active ingredients – such as live biotherapeutic products (LBPs), RNA and biologics – safely and effectively to the ileo-colonic region. By eliminating complex formulation steps, these functional capsules simplify oral drug development, helping customers to accelerate clinical timelines and bring innovative therapies to market faster.

“Oral drugs can transform treatment for patients worldwide. I am excited about the clinical and commercial opportunities possible with GMP-grade EUDRACAP® colon,” said Dr. Bettina Hölzer, Global Product Manager Oral Drug Delivery Solutions at Evonik Health Care.

**Evonik Industries AG**

Rellinghauser Straße 1-11  
45128 Essen  
Germany  
Phone +49 201 177-01  
www.evonik.com

Supervisory Board

Bernd Tönjes, Chairman  
Executive Board  
Christian Kullmann, Chairman  
Lauren Kjeldsen  
Dr. Claudine Mollenkopf  
Thomas Wessel

Registered Office is Essen  
Register Court Essen Local Court  
Commercial Registry B 19474

EUDRACAP® colon can be used for the delivery of sensitive active ingredients such as live biotherapeutics, oral biologics, proteins, peptides and nucleotides (RNA). These actives are used in the formulation of innovative drugs for the treatment of severe conditions such as obesity, HIV, or Cystic Fibrosis, as well as for local delivery such as for colorectal cancer and infections. There are currently more than 700 oral drug development programs using novel active ingredients. In fact, these new drug candidates make up around a third of all new oral drug developments in the pipeline.

EUDRACAP® colon is the latest innovation in Evonik's growing platform of functional capsules for oral drug delivery. This includes EUDRACAP® enteric for targeted drug release in the upper small intestine, EUDRACAP® Select for tailored CDMO services, and EUDRACAP® preclinic for early-stage development. The functional capsule platform is built on the trusted foundation of EUDRAGIT® polymers which is used in formulations across 80 countries and cited in over 23,000 patents.

Evonik Health Care offers integrated solutions that support pharmaceutical companies worldwide in bringing complex oral and parenteral drug products to market. At **CPHI Frankfurt 2025**, Evonik will showcase its portfolio of innovations including EUDRACAP® colon, PhytoSquene® – an award-winning plant-based squalene for parenteral use, its advanced parenteral excipients, CDMO services and biopharma solutions. Recent launches include MaxiPure® Polysorbate 80 for parenteral and biopharma applications.

### **Further Information**

Meet Evonik at CPHI Frankfurt Booth No. 5.1A24:  
<https://www.evonik.com/en/events/2025/cphi-frankfurt.html>

Learn more about the EUDRACAP® portfolio:  
<https://healthcare.evonik.com/en/drugdelivery/oral-drug-delivery/oral-excipients/eudracap-portfolio>

**Evonik: Leading beyond chemistry**

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

**About Custom Solutions**

The Custom Solutions segment focuses on innovation-driven, tailor-made solutions for customers in specific growth markets. These solutions include additives for coatings, adhesives and sealants, polyurethane foams and lubricants, catalysts, and ingredients for the cosmetics, cleaning and pharmaceutical industries. In 2024, the segment generated sales of €5.7 billion with around 7,000 employees.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.